EMA/113587/2014

European Medicines Agency decision
P/0072/2014

of 1 April 2014

on the acceptance of a modification of an agreed paediatric investigation plan for concentrate of proteolytic enzymes in bromelain (NexoBrid), (EMEA-000142-PIP02-09-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.
European Medicines Agency decision
P/0072/2014

of 1 April 2014

on the acceptance of a modification of an agreed paediatric investigation plan for concentrate of proteolytic enzymes in bromelain (NexoBrid), (EMEA-000142-PIP02-09-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency’s decision P/227/2010 issued on 28 October 2010, and the decision P/0122/2013 issued on 28 May 2013,

Having regard to the application submitted by MediWound Germany GmbH on 22 November 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 February 2014, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

---

Has adopted this decision:

**Article 1**

Changes to the agreed paediatric investigation plan for concentrate of proteolytic enzymes in bromelain (NexoBrid), powder and gel for gel, cutaneous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

**Article 2**

This decision is addressed to MediWound Germany GmbH, Eisenstr. 5, 65428 - Ruesselsheim, Germany.

Done at London, 1 April 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)
Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMEA-000142-PIP02-09-M03

Scope of the application

Active substance(s):
Concentrate of proteolytic enzymes in bromelain

Invented name:
NexoBrid

Condition(s):
Treatment of burns

Authorised indication(s):
See Annex II

Pharmaceutical form(s):
Powder and gel for gel

Route(s) of administration:
Cutaneous use

Name/corporate name of the PIP applicant:
MediWound Germany GmbH

Information about the authorised medicinal product:
See Annex II
Basis for opinion


The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 18 December 2013.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   • to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 14 February 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan
1. **Waiver**

Not applicable.

2. **Paediatric Investigation Plan**

2.1. **Condition: treatment of burns**

2.1.1. **Indication(s) targeted by the PIP**

Removal of eschar in deep partial and/or full thickness burns.

2.1.2. **Subset(s) of the paediatric population concerned by the paediatric development**

From birth to less than 18 years of age.

2.1.3. **Pharmaceutical form(s)**

Powder and gel for gel

2.1.4. **Studies**

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of studies</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Non-clinical</td>
<td>2</td>
<td><strong>Study 1</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SA single dose toxicity study of concentrate of proteolytic enzymes in bromelain powder administered intravenously to minipigs with a 14-day observation period.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Study 2</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>14-Day repeated intravenous dose study in juvenile pigs with collection of toxicokinetic data.</td>
</tr>
<tr>
<td>Clinical</td>
<td>3</td>
<td><strong>Study 3</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Multicentre trial to assess long-term scar formation and quality of life in adults and children aged from 4 to less than 18 years comparing debridement of burn wounds with concentrate of proteolytic enzymes in bromelain to standard of care.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Study 4</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Open-label, randomised, multicentre trial to evaluate pharmacokinetics, safety, efficacy and immunogenicity of concentrate of proteolytic enzymes in bromelain for debridement of partial thickness and full thickness thermal burns compared to standard of care in children aged from birth to less than 18 years.</td>
</tr>
<tr>
<td>Area</td>
<td>Number of studies</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Study 5</td>
<td></td>
<td>Multicentre trial to assess long-term scar formation and quality of life children after participating in study 4 comparing debridement with concentrate of proteolytic enzymes in bromelain to standard of care in children aged from birth to less than 18 years.</td>
</tr>
</tbody>
</table>

### 3. Follow-up, completion and deferral of PIP

| Concerns on potential long term safety and efficacy issues in relation to paediatric use: | No |
| Date of completion of the paediatric investigation plan: | By March 2019 |
| Deferral for one or more measures contained in the paediatric investigation plan: | Yes |
Annex II

Information about the authorised medicinal product
**Condition(s) and authorised indication(s):**

1. Treatment of burns

   **Authorised indication(s):**

   - NexoBrid is indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns.

**Authorised pharmaceutical form(s):**

Powder and gel for gel

**Authorised route(s) of administration:**

Cutaneous use